Latest P53 Stories
Zeroing in on the early cell mutations that enable a cancer to grow is one of the best ways to find a personalized therapy to stop it.
The genome of the most common form of ovarian cancer is characterized by a few common gene mutations but also surprisingly frequent structural changes in the genome itself.
A key for early diagnosis of cancer and personalized medicine is the order of genetic aberrations - deviations or irregularity - in individual cancers.
Scientists have begun to reveal the order of the genetic aberrations in individual cancers in a finding they say is key to early diagnosis and personalized medicine.
In addition to its damaging effect on the environment and its illegal smuggling into developing countries, researchers have now linked e-waste to adverse effects on human health, such as inflammation and oxidative stress â€“ precursors to cardiovascular disease, DNA damage and possibly cancer.
Temptations to exceed the speed limit are always plentiful, but only reckless drivers give in to such impulses.
Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53.
BEVERLY, Mass., April 11, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, is pleased to announce that their recent poster at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) generated significant interest from major Pharmaceutical companies and numerous investigators.
A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.
Experts from The Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Florida.
- Large; stout; burly.